Evidence map›Paper›PMID 35115001›Full record

ArticleBMC medical informatics and decision making2022

Evaluating the performance of temporal pattern discovery: new application using statins and rhabdomyolysis in OMOP databases.

M Lavallee, T Yu, L Evans, M Van Hemelrijck, C Bosco, A Golozar, A Asiimwe

Open access · goldAbstract read
In one paragraph

Article in BMC medical informatics and decision making, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

M LavalleeFormer Bayer Healthcare Pharmaceutical Inc, Whippany, NJ, USA. lavalleema@vcu.edu.
T YuLTS Computing LLC, West Chester, PA, USA.
L EvansLTS Computing LLC, West Chester, PA, USA.
M Van HemelrijckTranslational Oncology & Urology Research (TOUR), King's College London, London, UK.ORCID 0000-0002-7317-0858
C BoscoTranslational Oncology & Urology Research (TOUR), King's College London, London, UK.
A GolozarFormer Bayer Healthcare Pharmaceutical Inc, Whippany, NJ, USA.
A AsiimweBayer AG, Berlin, Germany.
Bayer (United States) · USKing's College London · GBBayer (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTemporal pattern discovery (TPD) is a method of signal detection using electronic healthcare databases, serving as an alternative to spontaneous reporting of adverse drug events. Here, we aimed to replicate and optimise a TPD approach previously used to assess temporal signals of statins with rhabdomyolysis (in The Health Improvement Network (THIN) database) by using the OHDSI tools designed for OMOP data sources.

methodsWe used data from the Truven MarketScan US Commercial Claims and the Commercial Claims and Encounters (CCAE). Using an extension of the OHDSI ICTemporalPatternDiscovery package, we ran positive and negative controls through four analytical settings and calculated sensitivity, specificity, bias and AUC to assess performance.

resultsSimilar to previous findings, we noted an increase in the Information Component (IC) for simvastatin and rhabdomyolysis following initial exposure and throughout the surveillance window. For example, the change in IC was 0.266 for the surveillance period of 1-30 days as compared to the control period of - 180 to - 1 days. Our modification of the existing OHDSI software allowed for faster queries and more efficient generation of chronographs.

conclusionOur OMOP replication matched the we can account forwe can account for of the original THIN study, only simvastatin had a signal. The TPD method is a useful signal detection tool that provides a single statistic on temporal association and a graphical depiction of the temporal pattern of the drug outcome combination. It remains unclear if the method works well for rare adverse events, but it has been shown to be a useful risk identification tool for longitudinal observational databases. Future work should compare the performance of TPD with other pharmacoepidemiology methods and mining techniques of signal detection. In addition, it would be worth investigating the relative TPD performance characteristics using a variety of observational data sources.

Indexed as

Drug-Related Side Effects and Adverse ReactionsHydroxymethylglutaryl-CoA Reductase InhibitorsRhabdomyolysisAdverse Drug Reaction Reporting SystemsDatabases, FactualElectronic Health RecordsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsAdverse eventsRhabdomyolysisStatinsTemporal pattern discover

Identifiers

PMID35115001
PMCPMC8812213
OpenAlexW4221021026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.